From a regulatory standpoint, this isn't just interesting it's a problem. Agencies evaluate drug products. They don't regulate psychotherapy. If a meaningful, inseparable portion of the treatment effect comes from the therapeutic container rather than the molecule, then defining the independent variable becomes genuinely complicated and your development program needs to address that directly.
-
2 Δημοσιεύσεις
-
1 τις φωτογραφίες μου
-
0 Videos
-
ζει στην USA
-
Από USA
-
ακολουθείται από 1 μέλη
© 2026 Soocian
Greek
Πρόσφατες ενημερώσεις
-
The Development Alignment GapWhy Clinical Development Programs Fail Before FDA Ever Reviews the Data A Strategic Perspective on Evidence Generation, Regulatory Alignment, and Development Success Denis Katz, MD Founder, Salience Clinical LLC Executive Summary Over the course of my career, I've participated in and advised development programs across pharmaceuticals, biologics, regenerative medicine, diagnostics, neuroscience...0 Σχόλια 0 Μοιράστηκε 205 Views 0 ΠροεπισκόπησηΠαρακαλούμε συνδέσου στην Κοινότητά μας για να δηλώσεις τι σου αρέσει, να σχολιάσεις και να μοιραστείς με τους φίλους σου!
-
0 Σχόλια 0 Μοιράστηκε 94 Views 0 Προεπισκόπηση
και άλλες ιστορίες